INTERMUNE INC
EXHIBIT 10.64
<DOCUMENT>
<TYPE>EX-10.64
<SEQUENCE>11
<FILENAME>f38745exv10w64.htm
<DESCRIPTION>EXHIBIT 10.64
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w64</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>&#091; * &#093; = Certain information on this page has been redacted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</B>
</DIV>




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.64</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">CONFIDENTIAL
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">VIA FAX AND FEDERAL EXPRESS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;7, 2004

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">David L. Snitman, Ph.D.<BR>
Chief Operating Officer<BR>
Array BioPharma, Inc.<BR>
3200 Walnut Street<BR>
Boulder, CO 80301

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>RE:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Amendment No.&nbsp;2 to the Drug Discovery Collaboration Agreement</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>(&#147;Amendment No.&nbsp;2&#148;)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Dr.&nbsp;Snitman:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As you know, InterMune, Inc. (&#147;<U>InterMune</U>&#148;) and Array BioPharma, Inc. (&#147;<U>Array</U>&#148;) are
parties to that certain Drug Discovery Collaboration Agreement dated September&nbsp;13, 2002, as amended
May&nbsp;8, 2003 (the &#147;<U>Agreement</U>&#148;). The parties agree that the Agreement is hereby amended as
follows, effective as of the date of this Amendment No.&nbsp;2 (&#147;<U>Amendment Effective Date</U>&#148;):
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The &#091; * &#093; is hereby removed as a &#091; * &#093; of the Agreement solely for the purpose of Array
entering into an &#091; * &#093; arrangement with a third party (the &#147;<U>Third Party</U>&#148;) for &#091; * &#093;,
and subject to the terms of this Amendment No.&nbsp;2. Accordingly:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>InterMune hereby waives its option to &#091; * &#093; under Section&nbsp;2.7.2 of the
Agreement solely with respect to such arrangement with the Third Party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If such arrangement with the Third Party has not been concluded within three
(3)&nbsp;months from the Amendment Effective Date as evidenced by an executed written
agreement, then &#091; * &#093; automatically will be reinstated as a &#091; * &#093; of the Agreement, and
all of InterMune&#146;s rights and Array&#146;s obligations under the Agreement with respect to &#091;
* &#093; will be reinstated in full. InterMune agrees that Array does not need to provide
InterMune with a copy of such written agreement, so long as InterMune receives by three
(3)&nbsp;months from the Amendment Effective Date a written certification, in the form
attached as Exhibit&nbsp;A hereto, from an authorized officer of Array that a written
agreement for such &#091; * &#093; arrangement has been executed. Any material misrepresentation
set forth in such certification will be deemed a material breach of this Amendment No.
2.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If such arrangement is concluded with the Third Party, but the &#091; * &#093; thereafter
revert to Array for any reason, then &#091; * &#093; automatically will be reinstated as a &#091; * &#093;
of the Agreement, and all of InterMune&#146;s rights and Array&#146;s obligations under the</TD>
</TR>

</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Agreement with respect to &#091; * &#093; will be reinstated in full. Array will give
InterMune prompt written notice of any such reversion.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Nothing in this Amendment No.&nbsp;2 will be deemed to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>grant to Array any further right, title or interest in or to
any intellectual property (including, without limitation, any patent rights)
Controlled by InterMune other than as expressly stated in Sections&nbsp;4.1.1 and
4.3 of the Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Array to use any Hit Compound, Lead Compound or Product for any
purpose other than the Research Collaboration conducted in accordance with the
Agreement; nor</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit Array to grant to any third party any right, title or
interest in or to any Hit Compound, Lead Compound or Product.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In consideration for InterMune&#146;s agreement as set forth in Section&nbsp;1 above, and irrespective
of the outcome of the negotiations or arrangement between Array and the Third Party:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(i)&nbsp;During the Research Term, Array shall provide, at its sole cost and
expense, &#091; * &#093; additional FTEs to conduct the Research Collaboration. Such additional
FTEs will bring the present number of FTEs conducting the Research Collaboration from &#091;
* &#093; to &#091; * &#093;. Each such individual shall have the appropriate skills, training,
experience and ability to perform his or her responsibilities under the Research Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Array fails to provide such additional FTEs as described in subsection
(a)(i) above, then in addition to any other remedies available to InterMune at law
or equity, InterMune shall be entitled to offset the costs of such additional FTEs
(based on the Array FTE Rate, as defined in Section&nbsp;5.1.2 of the Agreement) against
any amounts due to Array under the Agreement, including, without limitation, any
milestone and/or royalty payments.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except for purposes of the Research Collaboration conducted in accordance with
the Agreement, Array shall not develop (either pre-clinically or clinically), use,
import, make, have made, sell or offer for sale any Hit Compound, Lead Compound or
Product, including, without limitation, in conjunction with any other compound or
product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Array shall not enable (including without limitation through the grant of a
license or covenant) any Array Affiliate or Third Party to develop (either
pre-clinically or clinically), use, import, make, have made, sell or offer for sale any
Hit Compound, Lead Compound or Product, including, without limitation, in conjunction
with any other compound or product.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>&#091; * &#093; = Certain information on this page has been redacted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Array materially breaches this Amendment Number 2, then InterMune will be entitled to seek
any and all remedies available at law and or equity. Without limiting the generality of the
foregoing, in the event of any such material breach: (i) &#091; * &#093; automatically will be
reinstated as a &#091; * &#093; of the Agreement; and (ii)&nbsp;all of InterMune&#146;s rights and Array&#146;s
obligations under the Agreement with respect to &#091; * &#093; will be reinstated in full.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as set forth above, all terms and conditions of the Agreement will remain in full force and
effect. Any capitalized term used herein and not otherwise defined will have the same meaning as
set forth in the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please acknowledge your agreement to the above by having an authorized Array representative
countersign both enclosed copies of this Amendment No.&nbsp;2 where indicated below, and returning one
original to the attention of Gloria Lopez, Contracts Administrator, at InterMune. We would be
happy to proceed based on receipt of a facsimile copy while awaiting the original.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Sincerely,

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">/s/ Larry Blatt
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Larry Blatt<BR>
Vice President of Biopharmacology Research


</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="34%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>Acknowledged and Agreed:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>ARRAY BIOPHARMA, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ David Snitman
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">David Snitman</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">COO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-15-04</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">cc:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Paul Resnick, InterMune</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Counsel, Array BioPharma</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>&#091; * &#093; = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ARRAY BIOPHARMA, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OFFICER&#146;S CERTIFICATE</B>

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, hereby certifies that {he/she} is the duly elected
or appointed {Title} of ARRAY BIOPHARMA, INC., a Delaware corporation (the &#147;Company&#148;), and acting
in such capacity hereby certifies that:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(a)&nbsp;As of {Date}, the Company entered into a written agreement with a third party (the &#147;Third Party
Agreement&#148;) setting forth the terms of an &#091; * &#093; arrangement regarding the &#091; * &#093;, which agreement is
effective and binding on the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;The Third Party Agreement does not conflict with any obligation of the Company under the Drug
Discovery Collaboration Agreement between the Company and InterMune, Inc. (&#147;InterMune&#148;) dated
September&nbsp;13, 2002, as amended (the &#147;Agreement&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;The Company will promptly notify InterMune in writing upon any termination of the Third Party
Agreement or of any reversion of &#091; * &#093; to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;Any material misrepresentation set forth in this Certificate will be deemed a material breach
of the Agreement, and InterMune will be entitled to seek any and all remedies available at law and
or equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All capitalized terms used and not otherwise defined in this Certificate shall have the same
meanings as in the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, I have hereunto set my hand as of the day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2004.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>&#091; * &#093; = Certain information on this page has been redacted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
